Healthcare Resource Utilization and Associated Costs in New Users of Empagliflozin versus DPP-4 Inhibitors and GLP-1 Agonists: A Comparative Analysis Based on Retrospective Real-World Data from German Sickness Funds-Reference-Cited by-同舟云学术

Healthcare Resource Utilization and Associated Costs in New Users of Empagliflozin versus DPP-4 Inhibitors and GLP-1 Agonists: A Comparative Analysis Based on Retrospective Real-World Data from German Sickness Funds

Published:2022-05 Issue: Volume:Volume 14 Page:319-332
ISSN:1178-6981
Container-title:ClinicoEconomics and Outcomes Research
language:en
Short-container-title:CEOR

Author:

Wilke Thomas,Picker Nils,Müller Sabrina^ORCID,Stürmlinger Anna,Deiters Barthold,Dittmar Axel,Aberle Jens,Gabler Maximilian

Publisher

Informa UK Limited

Subject

Health Policy,Economics, Econometrics and Finance (miscellaneous)

Reference29 articles.

1. Projected number of people with diagnosed Type 2 diabetes in Germany in 2040

2. Kassenärztliche Bundesvereinigung, Bundesärztekammer. Nationale Versorgungsleitlinie Typ-2-Diabetes: Teilpublikation der Langfassung, 2. Auflage, [National care guideline for type 2 diabetes: partial publication of the long version, 2nd edition], Version 1. 2021. Available from: www.leitlinien.de. Accessed July 6, 2021. German.

3. Renal effects of SGLT2 inhibitors

4. Committee for Medicinal Products for Human Use (CHMP). Jardiance summary of opinion (post authorisation). Available from: https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-jardiance-ii-55_en.pdf. Accessed August 16, 2021.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Exploring Their Impact on Diabetes, Obesity, and Cardiovascular Health Through a Comprehensive Literature Review;Cureus;2024-09-01

2. Healthcare Resource Utilization and Costs for Empagliflozin Versus Glucagon-Like Peptide-1 Receptor Agonists in Routine Clinical Care in Denmark;Diabetes Therapy;2022-10-31